Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Psychological Factors Associated With Episodic Oral Chelation Adherence In Thalassaemia

Vosper Jane, D Clin Psy, Michael Evangeli, Clin Psy D, John Porter, MD, Farrukh Shah, MD

Blood (2013) 122 (21): 4706.

https://doi.org/10.1182/blood.V122.21.4706.4706

Published: 2013

Journal Articles

A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results

Maria-Domenica Cappellini, MD, John Porter, MD, Raffaella Origa, MD, Gian Luca Forni, MD, Adberrahmane Laadem, MD, Frédéric Galacteros, MD PhD, Dimana Miteva, PhD, Victoria Sung, PhD, Rajesh Chopra, MD, Jean-Benoît Arlet, MD, PhD, Jean-Antoine Ribeil, MD, PhD, Kenneth Klesczewski, PhD, Kenneth Attie, MD, Maciej Garbowski, MD, Olivier Hermine, MD, PhD

Blood (2013) 122 (21): 3448.

https://doi.org/10.1182/blood.V122.21.3448.3448

Published: 2013

Journal Articles

Assessment Of Non-Transfusional Iron Accumulation In Asian Patients With Hemoglobin E β Thalassemia

Tim G St Pierre, PhD, John Porter, MD, Angela Allen, PhD, Ashok Perera, MD, Dayananda Bandara, MD, A.B. Karunawathi, Anuja Premawardhena, MD, David J Weatherall, FRS, Nancy F Olivieri, MD

Blood (2013) 122 (21): 2262.

https://doi.org/10.1182/blood.V122.21.2262.2262

Published: 2013

Journal Articles

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

John Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Maria D Cappellini, Antonis Kattamis, MD, Ali El-Ali, MD, Nicolas Martin, MS, Dudley Pennell, MD, FRCP

Blood (2013) 122 (21): 1016.

https://doi.org/10.1182/blood.V122.21.1016.1016

Published: 2013

Journal Articles

Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study)

John Porter, MD, Patrick B Walter, PhD, Lynne D Neumayr, MD, Patricia Evans, PhD, Marcela G Weyhmiller, PhD, Paul Harmatz, MD, John C. Wood, MD, PhD, Jeffery L Miller, MD, Guenter Weiss, MD, Quing Yuan, PhD, Zhiyue J Wang, PhD, Regine Grosse, MD, Bjoern P Schoennagel, MD, Joerg Meerpohl, MD, Roland Fischer, PhD, Peter Nielsen, MD, Markus Seifert, BSc, Elliott Vichinsky, MD

Blood (2013) 122 (21): 1014.

https://doi.org/10.1182/blood.V122.21.1014.1014

Published: 2013

Journal Articles

Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine.

Patrick B. Walter, PhD, John Porter, MD, Patricia Evans, PhD, Janet L. Kwiatkowski, MD, Ellis J. Neufeld, MD, Thomas Coates, MD, Patricia J. Giardina, MD, Robert W. Grady, PhD, Elliott Vichinsky, MD, Nancy F. Olivieri, MD, Felicia Trachtenberg, PhD, Daniele Alberti, MD, Jaymes Holland, PhD, Ellen Fung, PhD, Bruce Ames, PhD, Annie Lui, BS, Paul Harmatz, MD

Blood (2007) 110 (11): 2773.

https://doi.org/10.1182/blood.V110.11.2773.2773

Published: 2007

Journal Articles

Leukocyte Apoptosis and Inflammation in Iron-Overloaded Patients with Sickle Cell Disease or β-Thalassemia: A Mechanism for Increased Stroke and Disease Severity in Sickle Cell Disease.

Patrick B. Walter, PhD, David W. Killilea, PhD, Ellen B. Fung, PhD, Annie Lui, BS, Jacqueline Madden, PNP, John Porter, MD, Patricia Evans, PhD, Bruce N. Ames, PhD, Elliott Vichinsky, MD, Paul Harmatz, MD

Blood (2006) 108 (11): 1233.

https://doi.org/10.1182/blood.V108.11.1233.1233

Published: 2006

Journal Articles

Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.

Patrick Walter, PhD, Eric Macklin, PhD, John Porter, MD, Patricia Evans, PhD, Tom Coates, MD, Nancy F. Olivieri, MD, Patricia Giardina, MD, Janet Kwiatkowski, MD, Ellis Neufeld, MD, Bruce Ames, PhD, Jaymes Holland, Peter Marks, MD, Elliott Vichinsky, MD, Paul Harmatz, MD

Blood (2005) 106 (11): 3598.

https://doi.org/10.1182/blood.V106.11.3598.3598

Published: 2005

Journal Articles

Hydroxyurea Treated Sickle Disorders Demonstrate Decreased Plasma Hb, Red Cell Vesicles and Thrombolysis.

Maxwell P. Westerman, MD, Arnold Pizzey, Jocelyn Hirshman, MPH, Mario Cerino, MD, Ada Eze, Andrew Lawrie, Gordon Purdie, Ian Mackie, John Porter, MD

Blood (2005) 106 (11): 2322.

https://doi.org/10.1182/blood.V106.11.2322.2322

Published: 2005

Journal Articles

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

John Porter, MD, Elliot Vichinsky, MD, Christian Rose, MD, Antonio Piga, MD, Nancy Olivieri, MD, Norbert Gattermann, MD, Johan Maertens, MD, Bertrand Rabault, PhD, Insa Gathmann, MSc, Daniele Alberti, MD

Blood (2004) 104 (11): 3193.

https://doi.org/10.1182/blood.V104.11.3193.3193

Published: 2004

Journal Articles

Toxic Unbound Iron and Membrane Injury in b-Thalassemia and Sickle Cell Disease: Elevated Non-Transferrin Bound Iron (NTBI) and Malondialdehyde (MDA).

Patrick B. Walter, PhD, Ellen Fung, PhD, David W. Killilea, PhD, Qing Jiang, PhD, Bruce N. Ames, PhD, Jacqueline Madden, PNP, Ellen Butensky, PhD, John Porter, MD, Patricia Evans, PhD, Paul Harmatz, MD, Elliott P. Vichinsky, MD

Blood (2004) 104 (11): 3608.

https://doi.org/10.1182/blood.V104.11.3608.3608

Published: 2004

Journal Articles

Prediction of Response to Recombinant Erythropoietin Plus Granulocyte-Colony Stimulating Factor Following a Single Subcutaneous Bolus in Patients with Myelodysplastic Syndromes; a Randomised Placebo Controlled Study.

David Bowen, MD, Ann Hyslop, BA, Norene Keenan, Michael Groves, Dominic Culligan, MD, Peter Johnson, MD, Ann Shaw, Fiona Geddes, Patricia Evans, BSc, John Porter, MD, Ivor Cavill, BSc

Blood (2004) 104 (11): 1435.

https://doi.org/10.1182/blood.V104.11.1435.1435

Published: 2004

Journal Articles

Plasma ‘Free’ HB Is Related to Red Cell Derived Vesicle Numbers in Sickle Cell Anemia and Thalassemia Intermedia: Implications for Nitric Oxide (NO) Scavenging and Pulmonary Hypertension.

Maxwell Westerman, MD, Arnold Pizzey, Jocelyn Hirschman, MPH, Mario Cerino, MD, Ada Eze, Priya Ramoton, Yonit Weil-Weiner, John Porter, MD

Blood (2004) 104 (11): 1671.

https://doi.org/10.1182/blood.V104.11.1671.1671

Published: 2004

NARROW

Psychological Factors Associated With Episodic Oral Chelation Adherence In Thalassaemia

A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results

Assessment Of Non-Transfusional Iron Accumulation In Asian Patients With Hemoglobin E β Thalassemia

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

Inflammatory and Vitamin Bio-Markers Of Iron Trafficking and Distribution In Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia With Sickle Cell Disease and Thalassemia (MCSIO PILOT Study)

Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine.

Leukocyte Apoptosis and Inflammation in Iron-Overloaded Patients with Sickle Cell Disease or β-Thalassemia: A Mechanism for Increased Stroke and Disease Severity in Sickle Cell Disease.

Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.

Hydroxyurea Treated Sickle Disorders Demonstrate Decreased Plasma Hb, Red Cell Vesicles and Thrombolysis.

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

Toxic Unbound Iron and Membrane Injury in b-Thalassemia and Sickle Cell Disease: Elevated Non-Transferrin Bound Iron (NTBI) and Malondialdehyde (MDA).

Prediction of Response to Recombinant Erythropoietin Plus Granulocyte-Colony Stimulating Factor Following a Single Subcutaneous Bolus in Patients with Myelodysplastic Syndromes; a Randomised Placebo Controlled Study.

Plasma ‘Free’ HB Is Related to Red Cell Derived Vesicle Numbers in Sickle Cell Anemia and Thalassemia Intermedia: Implications for Nitric Oxide (NO) Scavenging and Pulmonary Hypertension.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only